

Loxo Oncology Inc

COMPANY AND PIPELINE OVERVIEW REPORT

A comprehensive coverage of the company and a summary of the drug pipeline portfolio.

Publication Date: 06-Jul-2015

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT COMPANY AND PIPELINE OVERVIEW REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company and Pipeline Overview reports are the first in a series of reports that track pharmaceutical and biotechnology companies worldwide. Further report offerings planned to follow include: Company Detailed Pipeline and Company Competitive Landscape reports. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from a significant number of global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



PLEASE NOTE: the financials section where present in the report includes: Share Information, Stock Performance chart (including the consensus recommendation), and Major Shareholders. Financial Performance presents graphical and tabular data on Worldwide Sales, Operating Income and Net Income over time, together with a Quarterly earnings update. Balance Sheet lists Assets, Liabilities and Stockholders Equity, and Forecasts includes: EPS Forecast and Other Forecasts. The data reported in all sections (except share information and major stock holders) are correct as of the publication date of the report (and not the download date). For share information and major stock holders the data is correct for the date shown with these sections

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 7

Company Profile..... 7

Company Financials..... 7

Product Portfolio Summary..... 12

Product Portfolio Drugs..... 14

[Return to Table of Contents](#)

Loxo Oncology Inc

COMPANY OVERVIEW

Company Name	Loxo Oncology Inc
Parent Company Name	Loxo Oncology Inc
Website	http://www.loxooncology.com/
Country	US
Number of Drugs in Active Development	4
Number of Inactive Drugs	0
Number of Patents as Owner	0
Number of Patents as Third Party	0
Number of Deals	1
Key Indications	Cancer
Key Target-based Actions	FGF receptor antagonist,Flt3 tyrosine kinase inhibitor,Ret tyrosine kinase receptor inhibitor
Key Technologies	Small molecule therapeutic

COMPANY PROFILE

SUMMARY

Loxo Oncology, incorporated in Delaware in May 2013, is a biopharmaceutical company established and funded by Aisling Capital focused on cancer therapeutics.

FINANCIAL

In August 2014, the company was to sell 230,769 shares of its common stock, at a price of \$13 per share,through a private placement; in September 2014, the sale was completed.

In August 2014, the company priced its initial public offering of 5,261,538 shares of its common stock, at \$13 per share. The underwriters were granted a 30-day overallotment option to purchase up to an additional 789,230 shares of common stock. At that time, the shares began trading on National Association of Securities Dealers Automated Quotations under the symbol "LOXO"; in September 2014, the offering was closed.

In May 2014, the company raised \$24 million from a series B private financing round.

In October 2013, the company raised \$33 million from a series A financing round.

COMPANY FINANCIALS

SHARE INFORMATION

Close Price (USD)	17.12
Change (USD)	-1.04 (-5.73%)
Previous Close Price (USD)	18.16
Volume	55,385
52-Week High (USD)	21.48

[Return to Table of Contents](#)



52-Week Low (USD)	9.90
Date	02-Jul-2015
Exchange	NASDAQ(COMPOSITE)
Current Number of Shares Outstanding	16,687,436
Current Market Capitalization	285,688,904
EPS (Date Reported)	-1.24484

STOCK PERFORMANCE



MAJOR SHAREHOLDERS

Shareholder	Type	Country	Shares held	% of shares held	Change in holding	% changes in shares held	Date
Aisling Capital, LLC	Private Equity	United States	3,452,493	20.69	0	0	16-Apr-2015
OrbiMed Advisors, LLC	Investment Advisor/Hedge Fund	United States	2,175,857	13.04	0	0	16-Apr-2015
New Enterprise	Venture	United	1,792,207	10.74	0	0	16-Apr-2015

[Return to Table of Contents](#)




Associates (NEA)	Capital	States					
Array BioPharma, Inc.	Corporation	United States	1,014,860	6.08	1,014,860	1	16-Apr-2015
Driehaus Event Driven Fund	Mutual Fund	United States	243,267	1.46	0	0	30-Apr-2015
Bilenker (Joshua H)	Individual Investor	United States	188,707	1.13	0	0	16-Apr-2015
Naider (Avi Z)	Individual Investor	United States	155,345	0.93	79,863	1.06	16-Apr-2015
Flaherty (Keith T)	Individual Investor	United States	75,482	0.45	0	0	16-Apr-2015
iShares Russell 2000 ETF	Mutual Fund	United States	57,492	0.34	-7,501	-0.12	31-May-2015
VALIC Co I Small Cap Aggressive Growth Fund	Mutual Fund	United States	41,380	0.25	1,750	0.04	30-Apr-2015
Vanguard Total Stock Market Index Fund	Mutual Fund	United States	29,100	0.17	0	0	31-May-2015
Kunkel (Lori Anne)	Individual Investor	United States	26,840	0.16	26,840	1	16-Apr-2015
iShares Russell 2000 Growth ETF	Mutual Fund	United States	23,311	0.14	-800	-0.03	31-May-2015
Goldstein (Dov A)	Individual Investor	United States	22,656	0.14	0	0	16-Apr-2015
Fidelity Spartan Extended Market Index Fund	Mutual Fund	United States	18,269	0.11	0	0	31-May-2015
Dreyfus Select Managers Small Cap Growth Fund	Mutual Fund	United States	18,182	0.11	509	0.03	30-Apr-2015
BlackRock Small Cap Growth Equity Portfolio	Mutual Fund	United States	17,257	0.1	0	0	30-Apr-2015
Vanguard Extended Market Index Fund	Mutual Fund	United States	11,183	0.07	3,338	0.43	31-May-2015
Bailard, Inc.	Investment Advisor/Hedge Fund	United States	10,000	0.06	0	0	31-May-2015
Nationwide Bailard Technology & Science Fund	Mutual Fund	United States	10,000	0.06	0	0	31-May-2015

[Return to Table of Contents](#)



FINANCIAL PERFORMANCE

Sales and Income



	2013	2014			
Sales (USD M)	0	0			
Operating Income (USD M)	-10.29	-20.69			
Net Income (USD M)	-10.29	-20.672			

Quarterly earnings update

Period	Sales (USD M)	Operating Income (USD M)	Net Income (USD M)
2015 Q1	0	-6.225	-6.182
2014 Q4	0	-7.14	-7.122
2014 Q3	0	-6.743	-6.749
2014 Q2	0	-3.905	-3.922
2014 Q1	0	-2.902	-2.913

BALANCE SHEET

[Return to Table of Contents](#)



Assets (USD M)

	2013	2014			
Cash & Short Term Investments	14.994	106.292			
Inventories - Total	0	0			
Current Assets - Total	15.011	107.776			
Property, Plant And Equipment - Net		0.012			
Other Assets - Total	0.011	0.023			
Total Assets	15.022	114.459			

Liabilities (USD M)

	2013	2014			
Accounts Payable	0.221	0.239			
Short Term Debt & Current Portion Of Long Term Debt	0	0			
Current Liabilities - Total	0.41	1.787			
Long Term Debt	0	0			
Other Liabilities	0	0			
Total Liabilities	0.41	1.787			

Stockholders Equity (USD M)

	2013	2014			
Minority Interest	0	0			
Preferred Stock	30	0			
Common Stock	0	0.002			
Total Liabilities & Shareholders' Equity	15.022	114.459			

FORECASTS

[Return to Table of Contents](#)

EPS Forecast

Year ending	Current Forecast	1 month ago	3 months ago
31-Dec-2015	-1.72	-1.75	-2.01
31-Dec-2016	-1.84	-1.91	-2.01
31-Dec-2017	-3.22	-3.48	-3.42

Other Forecasts


Year ending	DPS	CPS	Pretax	Sales
31-Dec-2015			-30.07	0
31-Dec-2016			-32.37	16.67
31-Dec-2017			-68.13	0

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Neoplasm	4	0	4

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 1 Clinical	1
Discovery	3

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Development/Commercialization License	0	0	1	0	1

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Neoplasm	1	1

[Return to Table of Contents](#)

Trials by Phase

Phase	Ongoing	All
Phase 1	1	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUGS

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

LOXO-101

Drug Name	LOXO-101
Key Synonyms	
Originator Company	Array BioPharma Inc
Active Companies	Loxo Oncology Inc, Array BioPharma Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Cancer
Target-based Actions	Protein tyrosine kinase inhibitor, Tropomyosin inhibitor
Other Actions	Anticancer protein kinase inhibitor
Technologies	Oral formulation, Small molecule therapeutic
Last Change Date	12-Jun-2015

Loxo-102

Drug Name	Loxo-102
Key Synonyms	
Originator Company	Loxo Oncology Inc
Active Companies	Loxo Oncology Inc, Array BioPharma Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Ret tyrosine kinase receptor inhibitor
Other Actions	Anticancer protein kinase inhibitor
Technologies	Small molecule therapeutic
Last Change Date	03-Mar-2015

[Return to Table of Contents](#)



Loxo-103

Drug Name	Loxo-103
Key Synonyms	
Originator Company	Loxo Oncology Inc
Active Companies	Loxo Oncology Inc, Array BioPharma Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	FGF receptor antagonist
Other Actions	Anticancer protein kinase inhibitor
Technologies	Small molecule therapeutic
Last Change Date	03-Mar-2015

Loxo-104

Drug Name	Loxo-104
Key Synonyms	
Originator Company	Loxo Oncology Inc
Active Companies	Array BioPharma Inc, Loxo Oncology Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Cancer
Target-based Actions	Flt3 tyrosine kinase inhibitor
Other Actions	Anticancer protein kinase inhibitor
Technologies	Small molecule therapeutic
Last Change Date	03-Mar-2015

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

